OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

by Ilaria Colombo | 19 July 2024 | Women's Cancers

Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...
EU Recommends New Treatments for Endometrial and Urothelial Cancers

EU Recommends New Treatments for Endometrial and Urothelial Cancers

by EMA Approval | 12 July 2024 | Urogenital, Women's Cancers

The European Union has recommended new treatment options for patients with primary advanced or recurrent endometrial cancer and metastatic urothelial carcinoma. Durvalumab and Olaparib have been endorsed for endometrial cancer based on positive trial results, while...
Capivasertib Plus Fulvestrant Gains EU Approval for Advanced Breast Cancer

Capivasertib Plus Fulvestrant Gains EU Approval for Advanced Breast Cancer

by EMA Approval | 20 June 2024 | Women's Cancers

Capivasertib, in combination with fulvestrant, has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer. This approval targets patients with specific...
FDA Approves New Drugs for Endometrial Cancer and Ph-Negative BCP ALL

FDA Approves New Drugs for Endometrial Cancer and Ph-Negative BCP ALL

by FDA Approval | 18 June 2024 | Women's Cancers

The Food and Drug Administration (FDA) has approved new treatments for endometrial cancer and Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL). These advancements promise to enhance therapeutic options and improve...
Next Entries »

Recent Posts

  • Biomarkers in Gastrointestinal Cancers
  • Swissmedic Approvals for HR+ Metastatic Breast Cancer: T-DXd and Dato-DXd
  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Managing Pembro + EV Toxicities in Metastatic Urothelial Cancer

Recent Comments

  1. Swissmedic Approvals Expand Options for HR+ Metastatic Breast Cancer: Trastuzumab Deruxtecan and Datopotamab Deruxtecan | OncoViews on Breast Cancer Subtype Definitions (1/4)

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}